AAAAI, American Academy of Allergy, Asthma and Immunology; ACAAI, American College of Allergy, Asthma and Immunology; ACE2, Angiotensin-converting enzyme 2; ADCC, Antibody-Dependent Cell-mediated Cytotoxicity; AEs, Adverse events; Asthma; BTS, British Thoracic Society; Biologics; COVID-19; COVID-19, Coronavirus Disease 2019; DNA, Deoxyribonucleic acid; EBM, Evidence Based Medicine; ELF, European Lung Foundation; ERS, European Respiratory Society; FDA, Food and Drug Administration; GINA, Global Initiative for Asthma; GSK, Glaxo Smith Kline; ICS, inhaled corticosteroids; ICU, Intensive Care Unit; IL13, Interleukin 13; IL4, Interleukin 4; IL5, Interleukin 5; IL5Ra, Interleukin 5 alfa receptor; IL5r, Interleukin 5 receptor; IL6, Interleukin 6; IgE, Immunoglobulin E; NHLBI, National Heart, Lung, and Blood Institute; OCS, Oral corticosteroids; PDGFRA, Platelet-Derived Growth Factor Receptor A; PROSE study, Preventative Omalizumab or Step-up therapy for fall Exacerbations study; Pandemic; RCTs, Randomized Controlled Trials; SAEs, Serious Adverse Events; SARP, Severe Asthma Research Programme; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SC, Subcutaneous; SIAAIC, Italian Society of Allergy, Asthma and Clinical Immunology; Severe; T2, Type 2 inflammation; TMPRSS2, Transmembrane Protease Serine 2 Enzyme; Treatment; USA, United States of America; mAb, Monoclonal antibody